Double-Blind Comparison Between Mitiglinide and Nateglinide in Type 2 Diabetic Patients

• Status: Completed
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of Mitiglinide compared to Nateglinide for the treatment of type 2 diabetes.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kissei Pharmaceutical Co., Ltd.
• Treatments: Mitiglinide; Nateglinide

Criteria

Inclusion Criteria:

• Type 2 diabetes patients with inadequate control of blood glucose with diet and/or exercise therapy

Exclusion Criteria:

• Type 1 diabetes patients

• Patients who require treatment with insulin

• Patients with severe diabetic complications (neuropathy, retinopathy or nephropathy)

• Patients with severe ketosis, diabetic coma or precoma

• Patients complicated with severe hepatic diseases

• Patients complicated with severe renal diseases

• Patients complicated with severe hypertension

• Patients complicated with severe cardiac disease

• Pregnant women or women possible to be pregnant, nursing women, or women who want to become pregnant during the study period